Prosecution Insights
Last updated: November 04, 2026
Application No. 18/783,783

DECELLULARIZED MATRIX MATERIAL AND PREPARATION METHOD THEREFOR AND USE THEREOF

Non-Final OA §103§112
Filed
Jul 25, 2024
Priority
Jul 26, 2023 — CN 202310924645.3
Examiner
FIEBIG, RUSSELL G
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jiangsu Brightness Medical Devices Co. Ltd.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
566 granted / 904 resolved
+2.6% vs TC avg
Strong +25% interview lift
Without
With
+25.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
67 currently pending
Career history
951
Total Applications
across all art units

Statute-Specific Performance

§101
11.7%
-28.3% vs TC avg
§103
41.2%
+1.2% vs TC avg
§102
8.1%
-31.9% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 904 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s election without traverse of Group I, claims 1-8, in the reply filed on 30 September 2026 is acknowledged. Claims 9 and 10 are withdrawn as being directed to a nonelected invention. Claims 1-8 are presented for examination on the merits. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 is rendered vague and indefinite by the phrase “preparation method for a decellularized matrix material according to claim 1, wherein the preparation method comprises the following steps:…”. Since the claim is dependent on claim 1 and therefore includes all of the limitations of claim 1, it is unclear if the recited steps of claim 8 are additional steps or are meant to further define the steps of independent claim 1. That is – is step (1) of claim 8 meant to be the “pre-treatment” of claim 1 and step (2) the “swelling treatment”, etc.? It would seem appropriate that the method of claim 1 be itemized as in claim 8, i.e., steps (1), (2), (3), etc. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over CN 115 337 260 B (hereinafter “260) in view of Pandit et al. (US 7,550,152 B2). [REFS cited by Applicant in IDS filed 1/27/26]. “260 discloses decellularized small intestinal submucosa (SIS) tissue treated by soaking in saline, freezing, dissolving, i..e thawing, and treating with a surfactant, i.e. SDS, CHAPS and Triton X-100, to decellularize (D1: cl.1). “260 does not explicitly disclose a oxidase immersion treatment step. Pandit et al. discloses decellularized tissue, preferably SIS, treated by soaking in saline, treating with a surfactant, i.e. SDS, to decellularize and cross-linking with an oxidase (example and col.4-5 bridge par.). The technical effect of the distinguishing feature is that the sequence of steps including the oxidase immersion treatment before the surfactant treatment step results in a high decellularization efficiency as well as an intact collagen structure in the extracellular matrix. Table 1 shows equivalent decellularization performance with and without the oxidase step. The improved porosity and only shown in table 1 and figures 1-3 for the first three examples. This is due to the oxidase playing a buffering role in the tissue when the surfactant is applied, thereby ensuring the intactness of the collagen structure. It would have been obvious to one of ordinary skill in the art at the time of the effective filing date of the invention because it is know to use oxidase in the treatment of SIS, see Pandit et al., thus to provide an alternative the skilled person would include this as a step. In KSR, the Supreme Court indicated that the obviousness analysis should consider the “background knowledge possessed by a person having ordinary skill in the art.” KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398 (2007). Under KSR, information deemed within PHOSITA’s general knowledge is more powerful than that found buried in a prior art reference because we assume that PHOSITA would consider using their general knowledge in combination with the prior art — even absent any express motivation to do so. Under 35 U.S.C. § 103, the obviousness inquiry turns not only on the prior art, but whether “the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious . . . to a person having ordinary skill in the art to which the claimed invention pertains.” 35 U.S.C. § 103. Regardless of the tribunal, the inquiry into whether any “differences” between the invention and the prior art would have rendered the invention obvious to a skilled artisan necessarily depends on such artisan’s knowledge. Generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40oC and 80oC and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100oC and an acid concentration of 10%); See also, Peterson, 315 F.3d at 1330, 65 USPQ 2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references where held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ 2d 1843 (Fed. Cir.), cert denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ 2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ 2d 1362 (Fed. Cir. 1997). Accordingly, the instant claims, where no unexpected results are observed, would have been obvious to one of ordinary skill having the above cited references before him/her. Allowable Subject Matter It appears that claim 8 overcomes the above objection as it includes the step of a swelling with a 3-6M ZnCl2 solution, which corresponds to the one used in examples 1-3, and thus the effect discussed above is achieved. The problem is then considered as how to modify the method of “260 to result in an improved intactness of the collagen structure. In that case the skilled person finds no indication in ‘260 that performing this step before the surfactant treatment would result in an improved collagen/porous structure. In order to accord substantial weight to secondary considerations in an obviousness analysis, “the evidence of secondary considerations must have a ‘nexus’ to the claims, i.e., there must be ‘a legally and factually sufficient connection’ between the evidence and the patented invention.” Henny Penny Corp. v. Frymaster LLC, 938 F.3d 1324, 1332 (Fed. Cir. 2019) (quoting Demaco Corp. v. F. Von Langsdorff Licensing Ltd., 851 F.2d 1387, 1392 (Fed. Cir. 1988)). “The patentee bears the burden of showing that a nexus exists.” WMS Gaming Inc. v. Int’l Game Tech., 184 F.3d 1339, 1359 (Fed. Cir. 1999). “To determine whether the patentee has met that burden, we consider the correspondence between the objective evidence and the claim scope.” Henny Penny, 938 F.3d at 1332. Claim 8 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUSSELL G FIEBIG whose telephone number is (571)270-5366. The examiner can normally be reached M-F 8-4. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 5712720947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUSSELL G FIEBIG/Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jul 25, 2024
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779004
METHOD FOR HAIR CARE BY USING CASHEW TESTA EXTRACT
2y 5m to grant Granted Nov 03, 2026
Patent 12766090
COSMETIC USES OF A HIPPOPHAE RHAMNOIDES CAKE HYDROLYSATE
3y 4m to grant Granted Oct 20, 2026
Patent 12766091
COSMETIC USE OF AN OILY EXTRACT FROM DISTILLATION RESIDUE OF IMMORTELLE AS A SKIN BRIGHTENING AGENT
2y 10m to grant Granted Oct 20, 2026
Patent 12758581
Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative Recovery
3y 4m to grant Granted Oct 13, 2026
Patent 12741006
HERBO-LIPID COMPOSITION AND THE PROCESS FOR PREPARATION THEREOF
4y 10m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
88%
With Interview (+25.1%)
3y 0m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 904 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month